{"downloaded": true, "htmlmade": false, "full": {"id": "29912453", "source": "MED", "pmid": "29912453", "pmcid": "PMC6047453", "fullTextIdList": {"fullTextId": "PMC6047453"}, "doi": "10.1093/infdis/jiy214", "title": "Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.", "authorString": "de Vries RD, Altenburg AF, Nieuwkoop NJ, de Bruin E, van Trierum SE, Pronk MR, Lamers MM, Richard M, Nieuwenhuijse DF, Koopmans MPG, Kreijtz JHCM, Fouchier RAM, Osterhaus ADME, Sutter G, Rimmelzwaan GF.", "authorList": {"author": [{"fullName": "de Vries RD", "firstName": "Rory D", "lastName": "de Vries", "initials": "RD", "authorId": {"@type": "ORCID", "#text": "0000-0003-2817-0127"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands."}}}, {"fullName": "Altenburg AF", "firstName": "Arwen F", "lastName": "Altenburg", "initials": "AF", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands."}}}, {"fullName": "Nieuwkoop NJ", "firstName": "Nella J", "lastName": "Nieuwkoop", "initials": "NJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands."}}}, {"fullName": "de Bruin E", "firstName": "Erwin", "lastName": "de Bruin", "initials": "E", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands."}}}, {"fullName": "van Trierum SE", "firstName": "Stella E", "lastName": "van Trierum", "initials": "SE", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands."}}}, {"fullName": "Pronk MR", "firstName": "Mark R", "lastName": "Pronk", "initials": "MR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands."}}}, {"fullName": "Lamers MM", "firstName": "Mart M", "lastName": "Lamers", "initials": "MM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands."}}}, {"fullName": "Richard M", "firstName": "Mathilde", "lastName": "Richard", "initials": "M", "authorId": {"@type": "ORCID", "#text": "0000-0003-0240-9312"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands."}}}, {"fullName": "Nieuwenhuijse DF", "firstName": "David F", "lastName": "Nieuwenhuijse", "initials": "DF", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands."}}}, {"fullName": "Koopmans MPG", "firstName": "Marion P G", "lastName": "Koopmans", "initials": "MPG", "authorId": {"@type": "ORCID", "#text": "0000-0002-5204-2312"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands."}}}, {"fullName": "Kreijtz JHCM", "firstName": "Joost H C M", "lastName": "Kreijtz", "initials": "JHCM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands."}}}, {"fullName": "Fouchier RAM", "firstName": "Ron A M", "lastName": "Fouchier", "initials": "RAM", "authorId": {"@type": "ORCID", "#text": "0000-0001-8095-2869"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands."}}}, {"fullName": "Osterhaus ADME", "firstName": "Albert D M E", "lastName": "Osterhaus", "initials": "ADME", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands."}}}, {"fullName": "Sutter G", "firstName": "Gerd", "lastName": "Sutter", "initials": "G", "authorId": {"@type": "ORCID", "#text": "0000-0001-6143-082X"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Institute for Infectious Diseases and Zoonoses, Ludwig Maximilian University of Munich, Munich."}, {"affiliation": "German Center for Infection Research, Hannover, Germany."}]}}, {"fullName": "Rimmelzwaan GF", "firstName": "Guus F", "lastName": "Rimmelzwaan", "initials": "GF", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0001-6143-082X"}, {"@type": "ORCID", "#text": "0000-0001-8095-2869"}, {"@type": "ORCID", "#text": "0000-0002-5204-2312"}, {"@type": "ORCID", "#text": "0000-0003-0240-9312"}, {"@type": "ORCID", "#text": "0000-0003-2817-0127"}]}, "dataLinksTagsList": {"dataLinkstag": "altmetrics"}, "journalInfo": {"issue": "4", "volume": "218", "journalIssueId": "2707232", "dateOfPublication": "2018 Jul", "monthOfPublication": "7", "yearOfPublication": "2018", "printPublicationDate": "2018-07-01", "journal": {"title": "The Journal of infectious diseases", "ISOAbbreviation": "J Infect Dis", "medlineAbbreviation": "J Infect Dis", "NLMid": "0413675", "ISSN": "0022-1899", "ESSN": "1537-6613"}}, "pubYear": "2018", "pageInfo": "614-623", "abstractText": "<h4>Background</h4>High-pathogenicity avian influenza viruses continue to circulate in poultry and wild birds and occasionally infect humans, sometimes with fatal outcomes. Development of vaccines is a priority to prepare for potential pandemics but is complicated by antigenic variation of the surface glycoprotein hemagglutinin. We report the immunological profile induced by human immunization with modified vaccinia virus Ankara (MVA) expressing the hemagglutinin gene of influenza A(H5N1) virus A/Vietnam/1194/04 (rMVA-H5).<h4>Methods</h4>In a double-blinded phase 1/2a clinical trial, 79 individuals received 1 or 2 injections of rMVA-H5 or vector control. Twenty-seven study subjects received a booster immunization after 1 year. The breadth, magnitude, and properties of vaccine-induced antibody and T-cell responses were characterized.<h4>Results</h4>rMVA-H5 induced broadly reactive antibody responses, demonstrated by protein microarray, hemagglutination inhibition, virus neutralization, and antibody-dependent cellular cytotoxicity assays. Antibodies cross-reacted with antigenically distinct H5 viruses, including the recently emerged subtypes H5N6 and H5N8 and the currently circulating subtype H5N1. In addition, the induction of T cells specific for H5 viruses of 2 different clades was demonstrated.<h4>Conclusions</h4>rMVA-H5 induced immune responses that cross-reacted with H5 viruses of various clades. These findings validate rMVA-H5 as vaccine candidate against antigenically distinct H5 viruses.<h4>Clinical trials registration</h4>NTR3401.", "affiliation": "Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Clinical Trial, Phase I", "Randomized Controlled Trial", "Research Support, U.S. Gov't, Non-P.H.S.", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "HHSN272201400008C", "agency": "NIAID NIH HHS", "acronym": "AI", "orderIn": "0"}, {"grantId": "250136", "agency": "European Research Council", "orderIn": "0"}, {"grantId": "602604", "agency": "European Research Council", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "T-Lymphocytes", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Vaccinia virus", "meshQualifierList": {"meshQualifier": {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Vaccines, Synthetic", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Hemagglutinin Glycoproteins, Influenza Virus", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Influenza Vaccines", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antibodies, Viral", "meshQualifierList": {"meshQualifier": {"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Drug Carriers"}, {"majorTopic_YN": "N", "descriptorName": "Hemagglutination Inhibition Tests"}, {"majorTopic_YN": "N", "descriptorName": "Neutralization Tests"}, {"majorTopic_YN": "N", "descriptorName": "Immunization Schedule"}, {"majorTopic_YN": "N", "descriptorName": "Protein Array Analysis"}, {"majorTopic_YN": "N", "descriptorName": "Double-Blind Method"}, {"majorTopic_YN": "N", "descriptorName": "Cross Reactions"}, {"majorTopic_YN": "N", "descriptorName": "Antibody-Dependent Cell Cytotoxicity"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Influenza, Human", "meshQualifierList": {"meshQualifier": {"abbreviation": "PC", "qualifierName": "prevention & control", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Influenza A Virus, H5N1 Subtype", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Young Adult"}]}, "chemicalList": {"chemical": [{"name": "hemagglutinin, avian influenza A virus", "registryNumber": "0"}, {"name": "Antibodies, Viral", "registryNumber": "0"}, {"name": "Influenza Vaccines", "registryNumber": "0"}, {"name": "Vaccines, Synthetic", "registryNumber": "0"}, {"name": "Hemagglutinin Glycoproteins, Influenza Virus", "registryNumber": "0"}, {"name": "Drug Carriers", "registryNumber": "0"}]}, "subsetList": {"subset": [{"code": "AIM", "name": "Core clinical journals"}, {"code": "IM", "name": "Index Medicus"}]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1093/infdis/jiy214"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6047453"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6047453?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1093/infdis/jiy214"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "11", "hasData": "N", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2019-09-10", "dateOfCreation": "2018-06-19", "firstIndexDate": "2018-06-18", "fullTextReceivedDate": "2020-07-10", "dateOfRevision": "2019-09-10", "firstPublicationDate": "2018-07-01", "embargoDate": "2019-07-13"}, "abstract": "<h4>Background</h4>High-pathogenicity avian influenza viruses continue to circulate in poultry and wild birds and occasionally infect humans, sometimes with fatal outcomes. Development of vaccines is a priority to prepare for potential pandemics but is complicated by antigenic variation of the surface glycoprotein hemagglutinin. We report the immunological profile induced by human immunization with modified vaccinia virus Ankara (MVA) expressing the hemagglutinin gene of influenza A(H5N1) virus A/Vietnam/1194/04 (rMVA-H5).<h4>Methods</h4>In a double-blinded phase 1/2a clinical trial, 79 individuals received 1 or 2 injections of rMVA-H5 or vector control. Twenty-seven study subjects received a booster immunization after 1 year. The breadth, magnitude, and properties of vaccine-induced antibody and T-cell responses were characterized.<h4>Results</h4>rMVA-H5 induced broadly reactive antibody responses, demonstrated by protein microarray, hemagglutination inhibition, virus neutralization, and antibody-dependent cellular cytotoxicity assays. Antibodies cross-reacted with antigenically distinct H5 viruses, including the recently emerged subtypes H5N6 and H5N8 and the currently circulating subtype H5N1. In addition, the induction of T cells specific for H5 viruses of 2 different clades was demonstrated.<h4>Conclusions</h4>rMVA-H5 induced immune responses that cross-reacted with H5 viruses of various clades. These findings validate rMVA-H5 as vaccine candidate against antigenically distinct H5 viruses.<h4>Clinical trials registration</h4>NTR3401.", "journaltitle": "The Journal of infectious diseases", "authorinfo": ["de Vries RD", "Altenburg AF", "Nieuwkoop NJ", "de Bruin E", "van Trierum SE", "Pronk MR", "Lamers MM", "Richard M", "Nieuwenhuijse DF", "Koopmans MPG", "Kreijtz JHCM", "Fouchier RAM", "Osterhaus ADME", "Sutter G", "Rimmelzwaan GF"], "title": "Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial."}